<DOC>
	<DOCNO>NCT01799421</DOCNO>
	<brief_summary>The purpose study identify prognostic factor develop predictive model risk febrile neutropenia neutropenia grade 3/4 patient solid tumor receive chemotherapy schema inherent risk febrile neutropenia 10-20 % .</brief_summary>
	<brief_title>Risk Assessment Febrile Neutropenia Grade 3-4 Neutropenia Patients With Non-hematological Cancer Treated With Conventional Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Neutropenia</mesh_term>
	<mesh_term>Febrile Neutropenia</mesh_term>
	<criteria>Male female &gt; 18 year Histologically confirm solid tumor . Subjects receive chemotherapy / radiotherapy last 3 month . Subject initiate chemotherapy ( ie , cycle 1 , day 1 ) The chemotherapy regimen inherent risk febrile neutropenia 1020 % . Planning minimum 3 cycle chemotherapy . Adequate bone marrow reserve define : leukocyte ≥ 3,000 / mm3 , platelet ≥ 100.000/mm3 ; neutrophil ≥ 1,500 / mm3 . Adequate hepatic renal function , define : bilirubin &lt; 1.5 time normal value , ALT AST &lt; 3 time normal range ( elevate 5 time normal value patient know liver metastasis ) ; creatinine &lt; 1.5 time upper normal value ECOG ≤ 2 . Informed consent Patients treatment investigational treatment . Active infection last 72 h start chemotherapy . Indication chemotherapy dose intensity chemotherapy include risk rating febrile neutropenia &lt; 10 % &gt; 20 % . Patients concomitant chemoradiotherapy . Patients treat biological drug monotherapy . Any condition cause neutropenia . History bone marrow transplant stem cell .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>